Skip to main content

Table 2 Comparison of clinical and molecular characteristics of identified CRC subtypes

From: Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

iNMF step 1

Molecular feature

Type 1

Type 2

No. of tumor samples (AZTS)

28

34

No. of tumor samples (all datasets)

944

762

EMT expression signature

mesenchymal

epithelial

Survival prognosis

poor

good

Microsatellite status

similar number of MSI and MSS CRC

enriched with MSS CRC

iNMF step 2

Molecular feature

Subtype 1.1

Subtype 1.2

Subtype 1.3

Subtype 2.1

Subtype 2.2

No. of tumor samples (AZTS)

12

9

7

14

20

No. of tumor samples (all datasets)

313

303

328

313

449

Average percent tumor foci area

79.2

81.4

77.9

82.1

79.7

Average percent tumor cells in foci

76.3

74.5

80.0

73,8

73.7

Average percent stromal cells in foci

18.3

18.3

12.2

21.2

21.2

Average percent inflammatory cells in foci

3.8

7.2

6.4

3.5

4.7

EMT expression signature

strongly mesenchymal

mesenchymal

mesenchymal

epithelial

epithelial

Tumor location colon/left/rectum/right

0/26/16/15

1/12/1/29

0/12/2/11

1/22/9/37

1/50/11/33

Microsatellite status MSI/MSS

14/15

42/9

2/35

27/31

4/50

Tumor stage

enriched in late stage CRC

    

Gender enrichment Female/Male/Unknown

87/99/0

89/57/0

90/124/1

58/34/0

108/113/0

Up-regulated genes

Ca-signaling and SRF-targeted

immune system-related

transporters

stress response and immune system-related

cell cycle and amino acid synthesis; genes on 13q13, 13q14, 13q32-34 and 20q11and 20q13

  1. Differences in these characteristics were assessed using all datasets with available annotation.